Trials / Terminated
TerminatedNCT02057211
Mesenchymal Stem Cells to Intervene in the Development of Type 1 Diabetes: a Blinded Randomized Study
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Uppsala University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
This project aims to evaluate the efficacy of autologous mesenchymal stem cell treatment to preserve insulin production and beta-cell mass in recently diagnosed patients with type 1 diabetes mellitus. The hypothesis to be tested is that an increased number of circulating mesenchymal stem cells will provide immune modulatory properties, and thereby stop the immune process in islets causing progressive beta-cell death.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | autologous mesenchymal stem cell transplantation | |
| PROCEDURE | sham transplantation of mesenchymal stem cells | Placebo control for transplantation of mesenchymal stem cells |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2017-11-01
- Completion
- 2017-11-01
- First posted
- 2014-02-07
- Last updated
- 2020-11-06
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT02057211. Inclusion in this directory is not an endorsement.